Rezlidhia

olutasidenib

Approval

ApplicationNDA 215814
Approval dateDec 1, 2022
Approval year2022
SponsorRigel Pharms

FDA-approved use

To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Rezlidhia: